George Yancopoulos, Regeneron president and CSO (Brendan McDermid/Reuters/Alamy)
February 18, 2022 07:17 AM ESTUpdated March 7, 11:28 AM
R&D

In sur­prise flop, Re­gen­eron, Sanofi re­port Dupix­ent PhI­II fail­ure, trig­ger­ing pre­ma­ture tri­al stop

Amber Tong

Dupix­ent, the seem­ing­ly in­fal­li­ble an­ti-in­flam­ma­to­ry drug joint­ly de­vel­oped by Re­gen­eron and Sanofi, has flopped in a Phase III study.

Giv­en to pa­tients with chron­ic spon­ta­neous …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

A service from the Financial Times